Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q7Z6B7
UPID:
SRGP1_HUMAN
Alternative names:
Rho GTPase-activating protein 13
Alternative UPACC:
Q7Z6B7; Q9H8A3; Q9P2P2
Background:
SLIT-ROBO Rho GTPase-activating protein 1, alternatively known as Rho GTPase-activating protein 13, plays a pivotal role in cellular processes by acting as a GTPase-activating protein for RhoA and Cdc42 small GTPases. It is instrumental in neuronal migration, mediating the repulsive signaling of Robo and Slit proteins, with SLIT2 enhancing its interaction with ROBO1 to inactivate CDC42.
Therapeutic significance:
The protein's association with non-medullary thyroid cancer, a prevalent form of thyroid cancer, underscores its potential as a therapeutic target. Understanding the role of SLIT-ROBO Rho GTPase-activating protein 1 could open doors to novel therapeutic strategies for managing this disease.